Users Coming Off Anti-Obesity Injections Gain Back Weight at a Quadrupled Rate Than People Using Diet and Exercise

Fresh analysis reveals that individuals who stop using new slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who end traditional lifestyle programs.

Findings released in a prominent health publication demonstrates that while obese individuals can lose a large proportion of their total mass while on the medication, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.

"People using these medications must be aware of the potential of quick rebound weight gain when the therapy is stopped," warns researcher Dr. Susan Jebb.

That rate of recovery means a return to pre-treatment weight in about 18 months.

Weighing Approaches

The analysis, which looked at dozens of studies involving thousands of patients, compared the outcomes of GLP-1 agonists with conventional dieting.

Researchers emphasize that people who shed pounds through lifestyle changes alone usually experience a less rapid creep back—approximately 0.1 kg a month—once they finish.

Explaining the Quick Regain

Experts propose the way of the jabs explains the accelerated regain.

The injections imitate a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.

"Artificially providing the hormone concentrations far above than the body's typical production could lead to the system to produce less of its own natural hormone, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.

"Discontinuation of this GLP-1 'fix' leads to appetite is uncontrolled, making excessive eating much more probable."

A Lifelong Issue?

Medical guidelines advise the jabs for people with obesity-related health risks, accompanied by prescribed lifestyle changes.

Many experts say that, given the significant potential of weight regain, the treatment should be considered long-term.

This opinion is echoed by drug manufacturers, who state that the findings "highlight the persistent nature of excess weight," similar to managing conditions like diabetes.

User Experiences

People who have come off the medication explain a intense resurgence of appetite.

"It was like a switch that goes on and I was suddenly ravenous," described a patient.

This challenge is exacerbated if users have not adopted sustainable lifestyle or habit modifications during therapy.

Growing Adoption

Figures show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.

• Use is higher among females compared to men.
• The 40s and 50s age group shows the highest usage rates.
• A large proportion access the drugs through private healthcare rather than public health services.

In conclusion, experts stress that while the jabs are powerful agents for weight loss, they are not a permanent solution and maintained weight loss hinges on integrated lifestyle management.